Allon Therapeutics Inc.
TSX : NPC

Allon Therapeutics Inc.

December 07, 2006 09:15 ET

Allon Therapeutics Presents at IBC's EuroTIDES Conference

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 7, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company™, presented a case study during IBC's EuroTIDES 2006 conference: Oligonucleotide, RNAi and Peptides for the Drug Development and Manufacturing Industry in Hamburg, Germany.

The presentation, entitled "Neuropeptide development: Preclinical challenges in pharmacokinetics and pharmacodynamics - lessons learned from the NAP peptide", provided an update on the understanding of how NAP, the core element of Allon's Phase II drug, reaches its target within the central nervous system. The presentation was given from Dr. Bruce Morimoto, Vice President of Drug Development of Allon Therapeutics on December 5th, 2006.

Dr. Morimoto's presentation explained that following both the intranasal administration of AL-108 and the intravenous administration of AL-208, drug appeared rapidly in the plasma, cerebrospinal fluid and the brain. Quantitative whole body autoradiography results have provided a detailed picture of the pharmacokinetics of AL-108 and AL-208, thereby providing a link to understanding the pharmacodynamics of appearance in the cerebrospinal fluid and brain.

"The findings of this study continue to support Allon entering into multiple Phase II human clinical trials with AL-108 and AL-208," said Morimoto. "Understanding the formulations and routes of administration are key for Allon in their pursuit for treatments that halt or prevent acute and chronic neurodegenerative conditions."

AL-108 and AL-208 are eight amino acid neuropeptides that are in Phase II trials, having shown preclinical efficacy in a number of neurodegenerative models. AL-108 is Allon's intranasal neuroprotective product, that has completed two Phase I human clinical trials for the treatment of Alzheimer's disease and recently received IRB approval for initiation of a Phase II trial. AL-208 is an intravenous product in an ongoing Phase II human clinical trial testing for the prevention of mild cognitive impairment associated with post-coronary artery bypass graft surgery.

The peptide study was carried out by NoAb Biodiscoveries in Missisauga and Montreal-based Charles River Canada, part of Charles River Laboratories Inc. (NYSE:CRL), a leading contract research organization for drug development services.

About Allon

Allon Therapeutics Inc. is a clinical-stage Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's, cognitive impairment, stroke, traumatic brain injury, multiple sclerosis and neuropathy. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver.

Forward-Looking Statements

There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Allon's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Allon's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.


Contact Information